Leading Edge Genomic Services & Solutions


The Novogene Precision Medicine (NovoPMTM) cancer panel is a next-generation sequencing-based assay that analyzes more than 500 genes for clinically important alterations. These genes are known to be relevant for the diagnosis and/or treatment of various solid tumors according to National Comprehensive Cancer Network (NCCN) guidelines and medical literature.



~500 solid tumor-related genes including selected introns from 21 genes

4 classes of genomic alterations (SNV, InDel, CNV, and Fusion)

3 algorithms (TMB, bTMB and MSI) specific for informing immunotherapy decisions


Applicable to both Tissue and Blood samples

Paired tumor/normal samples or tumor sample alone


Comprehensive analytical validation

Rigorous quality control

State-of-the-art bioinformatics pipeline

For Research Use Only: The content provided herein may relate to products that have not been officially approved by healthcare authorities in China and is thus for research use only. The content of this document is subject to change without notice. 2018 Novogene Co., LTD. All rights reserved. All trademarks are the property of Novogene Co., LTD and its subsidiaries unless otherwise specified.